66 biotech companies
Symposium Bioproduction 2010
Program
THE 3rd GENOPOLE INTERNATIONAL SYMPOSIUM ON BIOMANUFACTURING
30 years of therapeutic product biomanufacturing: outcomes and outlook
Tuesday, December 14th 2010
| 8:00 | Registration |
| 8:45 – 9:00 | Opening and welcome address by Pierre Tambourin, CEO of Genopole® |
| INTRODUCTION | 30 YEARS OF THERAPEUTIC PRODUCT BIOMANUFACTURING |
| Chair | Didier HOCH
Sanofi-Pasteur MSD, France |
| 9:00 | William G. Whitford,
Thermo Fisher Scientific, USA 30 years of approved recombinant cell culture products |
| 9:30 | Jean-Hugues Trouvin,
EMA / Paris Descartes / APHP-AGEPS, France Biotech-derived medicines; the conclusions of an assessment by the European Medicines Agency and outlook |
| 10:00 | Tarkan Dogru,
Novartis Biotech, Huningue, France Moving BioPharmOps Huningue to a multiple products facility |
| 10:30 | Rémi Gloeckler,
Transgène From the dream to reality and from the bench to the factory: a biotech firm changes its business model |
| 11:00-11:30 | Coffee break and exhibition |
| 11:30 | Nadège Penhaleux-Halet,
Alcimed, France Vaccine technologies: recent breakthroughs and new approaches for pandemic vaccines |
| 12:00 | Clarence Deffaud,
Biotem, France Monoclonal antibodies for use in R&D, diagnostics and therapy: development strategies |
| 12:30 | Alain Beck,
Centre d’Immunologie Pierre Fabre, France Development strategies and challenges for the next generation of therapeutic antibodies and derivatives |
| 13:00 | Lunch |
|---|
| 14:15 | Cédric Guillerme ,
Ministère de l’Economie, de l’Industrie et de l’Emploi Direction Générale de Compétitivité, de l’Industrie et des Services Presentation of the market study on French Biomanufacturing |
| IMPLEMENTING ALTERNATIVE EXPRESSION SYSTEMS VIA THE DEVELOPMENT OF APPROPRIATE TECHNOLOGIES | ALTERNATIVE EXPRESSION SYSTEMS
First Part | |||
| Chair | Michel Gigon,
Laporte Experts Conseil, Canada | Chair | Jean-Loup Faulon,
ISSB (Institut de Biologie Systémique et Synthétique) , France | |
| 14:45 | Patrick Hible, Senior Process Expert
Pharmaceutical & Biotechnology, Technip France New challenges in the design and construction of an upgradeable production facility | 14:45 | Loïc Faye ,
Angany Genetics, France
Success Stories In Molecular Farming - From Bench To Bedside | |
| 15:15 | Peter Wagner,
Cosmix Therapeutics, Germany High Affinity Ligands (HAL), a new generation of biotherapeutics | 15:15 | Pr. Frédéric Bourgaud, Vice-Président
Recherche, Plant Advanced Technologies, France _ New plant models and bioprocesses to produce recombinant therapeutical proteins and bioactive compounds | |
| 15:45 | Louis Vezina, CSO,
Medicago, Canada The VLPExpress high-throughput antigen presentation screening platform – value in novel vaccine development | 15:45 | Claude Gudin, Consultant Expert, France
Applications of microalgae | |
| 16:15 | Carsten Müller,
m2p-labs GmbH, Allemagne Integral solution for high throughput screening of clones and media composition in online monitored shaken microbioreactors | 16:15 | Gilles Marchal, President & CSO
Immunotherapix, France Production of ITP-01, an anti-inflammatory derived by extended freeze-drying of BCG | |
| 16:45-17:15 | Pause | |
|---|---|---|
| BIOSIMILARS AND BIOGENERICS: THE OUTLOOK | ALTERNATIVE EXPRESSION SYSTEMS
Second part | |||
| Chair | To be confirmed | Chair | Jean-Loup Faulon,
ISSB (Institut de Biologie Systémique et Synthétique) , France | |
| 17:15 | Jean-Louis Prugnaud, Chef de Service,
Hôpital Saint Antoine, Paris, France
Why do we say “biosimilars” and not “biogenerics”? | 17:15 | Majid Mehtali, CSO et Managing Director,
Vivalis, France Building on the unique biological properties of embryonic stem cells for the large-scale industrial manufacture of biological products | |
| 17:45 | Gail Dutton, Writer for GEN
Genetic Engineering & Biotechnology News The US Pathway to Biosimilars | 17:45 | Franck Zal, CEO & CSO,
Hemarina SA, France HEMARINA-M101 and HEMARINA-M201, two families of hemoglobin from marine organisms for therapeutic and industrial applications | |
| 18:15 | Sami N Guzder
Science & Innovation, Avesthagen, Bangalore, India | 18:15 | Marc Delcourt,
Global Bioenergies, France Converting renewable resources into light olefins, the core platform molecules of the petrochemical industry | |
| 18:45 | Discours de clôture
Frédéric Revah, Genethon, France | |
